Roquefort Therapeutics (LON:ROQ) Stock Price Down 14.3% – Here’s Why

Roquefort Therapeutics plc (LON:ROQ)’s stock price dropped 14.3% on Tuesday . The stock traded as low as GBX 1.20 and last traded at GBX 1.20. Approximately 91,330 shares were traded during trading, a decline of 96% from the average daily volume of 2,182,829 shares. The stock had previously closed at GBX 1.40.

Roquefort Therapeutics Trading Down 14.3%

The company has a market capitalization of £1.89 million, a P/E ratio of -1.90 and a beta of 0.05. The company has a 50-day simple moving average of GBX 1.64 and a 200 day simple moving average of GBX 1.67. The company has a debt-to-equity ratio of 12.37, a quick ratio of 3.07 and a current ratio of 0.79.

Roquefort Therapeutics (LON:ROQ) last announced its quarterly earnings data on Tuesday, September 30th. The company reported GBX (0.33) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative return on equity of 29.57% and a negative net margin of 57,057.07%.

Insider Transactions at Roquefort Therapeutics

In related news, insider Dr Darrin Disley acquired 5,000,000 shares of the company’s stock in a transaction dated Friday, November 21st. The shares were bought at an average price of GBX 170 per share, for a total transaction of £8,500,000. 23.53% of the stock is owned by corporate insiders.

About Roquefort Therapeutics

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.